ULTRAGENYX PHARMACEUTICAL INC. Operating Lease, Liability, Noncurrent
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Operating Lease, Liability, Noncurrent of $24.00 million as of 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-02-18
- 2025-12-31: Operating Lease, Liability, Noncurrent $24.00M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $21.69M.
- 2025-06-30: Operating Lease, Liability, Noncurrent $24.53M.
- 2025-03-31: Operating Lease, Liability, Noncurrent $27.79M.
| Period end | Operating Lease, Liability, Noncurrent | Operating Lease, Liability, Noncurrent as first filed |
|---|---|---|
| 2025-12-31 | $24.00M 10-K · filed 2026-02-18 | |
| 2025-09-30 | $21.69M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $24.53M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $27.79M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $30.00M 10-K · filed 2026-02-18 | $30.04M 10-K · filed 2025-02-19 |
| 2023-12-31 | $30.57M 10-K · filed 2025-02-19 | |
| 2022-12-31 | $19.81M 10-K · filed 2023-02-17 | |
| 2021-12-31 | $30.49M 10-K · filed 2022-02-15 | |
| 2020-12-31 | $38.55M 10-K · filed 2021-02-12 | |
| 2020-09-30 | $36.67M 10-Q · filed 2020-10-27 | |
| 2020-06-30 | $36.31M 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $34.96M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $29.76M 10-Q · filed 2020-10-27 | |
| 2019-09-30 | $31.21M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $32.97M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $22.98M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |